Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment

Clin Infect Dis. 2022 Feb 11;74(3):532-540. doi: 10.1093/cid/ciab625.

Abstract

Prompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication after antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients seems to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modeling studies indicate that early treatment could have major epidemiologic benefits in seasonal and pandemic influenza.

Keywords: antiviral; baloxavir; influenza; oseltamivir; transmission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents* / therapeutic use
  • Drug Resistance, Viral
  • Humans
  • Influenza, Human* / drug therapy
  • Influenza, Human* / prevention & control
  • Neuraminidase
  • Orthomyxoviridae*
  • Oseltamivir / therapeutic use
  • Virus Replication

Substances

  • Antiviral Agents
  • Oseltamivir
  • Neuraminidase